InvestSMART

Clinuvel Pharmaceuticals Limited (ASX:CUV)

ALERT: Price-sensitive ASX Announcement for CUV
Current share price for CUV : $9.100 -3.54 (-28.01%)+
Announcement
Release
12 Jan 2026 8:42AM
Price at Release
$12.640
Full Release
download
Summary
Clinuvel Pharmaceuticals Limited announced the commencement of dosing in a preclinical study using its VLRX-L injectable peptide platform, which is designed to control the release of peptides through a liquid dose. This study aims to evaluate the safety, kinetics, and controlled-release profile of VLRX-L candidates using an in-vitro model. The VLRX-L platform is the first pharmaceutical platform to enter preclinical testing from their Singapore RD&I Centre, following years of R&D work on peptides and delivery systems. The company plans to complete the preclinical program by the second half of 2026. The VALLAURIX RD&I Centre was expanded in December 2025, supported by a five-year investment plan with the Singaporean Economic Development Board, to enhance its formulation capabilities.
Key Points
  • Clinuvel starts preclinical study for injectable peptide platform VLRX-L.
  • VLRX-L is designed for controlled-release of peptides including melanocortins.
  • Preclinical study focuses on safety, kinetics, and reproducibility of drug release.
  • VLRX-L is the first platform from Clinuvel's Singapore RD&I Centre.
  • Completion of the preclinical program is expected by H2 2026.
  • Expansion of VALLAURIX RD&I Centre to support injectable formulations.
  • Investment plan supported by Singaporean Economic Development Board.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.